Bionik Laboratories Corp.
BNKL · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | 0.02 | -0.01 |
| FCF Yield | -122.66% | -189.81% | -36.06% | -111.89% |
| EV / EBITDA | -0.99 | -0.02 | -1.22 | -0.33 |
| Quality | ||||
| ROIC | -448.84% | -149.90% | -84.28% | -73.04% |
| Gross Margin | 54.83% | 74.84% | 77.41% | 58.51% |
| Cash Conversion Ratio | 0.68 | 0.40 | 0.34 | 0.36 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.79% | -16.06% | -28.36% | 29.68% |
| Free Cash Flow Growth | 18.57% | 10.04% | 49.87% | 1.19% |
| Safety | ||||
| Net Debt / EBITDA | -0.42 | 0.21 | -0.24 | 0.01 |
| Interest Coverage | -45.03 | -5.78 | -15.19 | -61.82 |
| Efficiency | ||||
| Inventory Turnover | 0.79 | 0.27 | 0.39 | 0.84 |
| Cash Conversion Cycle | 305.10 | 1,087.84 | 459.52 | 229.27 |